Veru Inc. (NASDAQ:VERU) is a biopharmaceutical company that focuses on developing treatments for cardiometabolic and inflammatory diseases. On August 11, 2025, Veru implemented a reverse stock split at a ratio of 10 for 1. This means that for every 10 shares of Veru's common stock, shareholders now hold one share. The reverse stock split is a strategic move to consolidate shares and potentially increase the stock's market price.
The reverse stock split took effect at 11:59 pm CT on August 8, 2025, and Veru's stock began trading on a split-adjusted basis on the Nasdaq Capital Market on August 11, 2025. The stock continues to trade under the symbol VERU, but with a new CUSIP number, 92536C202. This change affects not only the common stock but also all outstanding stock options, stock appreciation rights, and equity incentive plans, which are adjusted proportionally.
VERU's stock price was $3.59, reflecting a decrease of approximately 3.68% or $0.137. During the trading day, the stock fluctuated between a low of $3.42 and a high of $3.80. Over the past year, the stock has seen a high of $14.20 and a low of $3.33. The reverse stock split aims to stabilize the stock price and potentially attract more investors by reducing the number of shares available.
Veru's market capitalization is approximately $52.6 million, with a trading volume of 469,193 shares on the NASDAQ exchange. The reverse stock split does not change the company's market capitalization but reduces the number of shares outstanding, which can lead to a higher stock price. This move is often used by companies to meet stock exchange listing requirements or to make the stock more attractive to institutional investors.
